Immunotherapy Now First Line for Esophageal Cancer
Nivolumab (Opdivo) with chemotherapy or in combination with ipilimumab (Yervoy) has been approved by the FDA for first-line use in the treatment of unresectable advanced or metastatic esophageal cancer.
FDA Approvals
source https://www.medscape.com/viewarticle/974800?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/974800?src=rss
Comments
Post a Comment